Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Sanofi ( (SNY) ) is now available.
In January 2025, Sanofi announced significant advancements in the treatment of multiple myeloma with Sarclisa’s new subcutaneous formulation. The IRAKLIA phase 3 study demonstrated that the subcutaneous delivery via an on-body delivery system met co-primary endpoints, showing comparable efficacy and safety to the intravenous method. This development could ease treatment delivery for patients and potentially reduce time spent in healthcare facilities. Additionally, Sarclisa obtained its first approval in China for treating adult patients with relapsed or refractory multiple myeloma, signaling an expansion of its global reach and impact.
More about Sanofi
Sanofi is a global healthcare company focused on providing innovative treatments and life-saving vaccines. Their efforts are directed towards advancing oncology and immunoscience, with a particular emphasis on difficult-to-treat cancers and diseases with unmet medical needs. Sanofi is committed to transforming medicine and is listed on EURONEXT and NASDAQ.
YTD Price Performance: 0.87%
Average Trading Volume: 2,309,198
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $123B
Find detailed analytics on SNY stock on TipRanks’ Stock Analysis page.